Kinase Inhibitor Larotrectinib Shows Durable Anti-Tumor Abilities in Patients of All Ages with 17 Unique Cancer Diagnoses
University of Texas MD Anderson Cancer CenterThree simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses.